<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028756</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC 30994</org_study_id>
    <secondary_id>EORTC-30994</secondary_id>
    <secondary_id>CDR0000069130</secondary_id>
    <secondary_id>CAN-NCIC-EORTC-30994</secondary_id>
    <secondary_id>ACOSOG-EORTC-30994</secondary_id>
    <secondary_id>NCRI-BLADDER-EORTC-30994</secondary_id>
    <secondary_id>UKCCCR-EORTC-30994</secondary_id>
    <secondary_id>FNCLCC-GETUG-EORTC-30994</secondary_id>
    <secondary_id>N02CM62212</secondary_id>
    <secondary_id>2005-003741-13</secondary_id>
    <nct_id>NCT00028756</nct_id>
  </id_info>
  <brief_title>Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium</brief_title>
  <official_title>Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe D'Etude des Tumeurs Uro-Genitales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft Urologische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      Randomized phase III trial to compare the effectiveness of immediate adjuvant chemotherapy
      with that of adjuvant chemotherapy given when the cancer returns in treating patients who
      have undergone a radical cystectomy for stage III or stage IV transitional cell carcinoma of
      the bladder urothelium. Drugs used in chemotherapy use different ways to stop tumor cells
      from dividing so they stop growing or die. Combining more than one drug and giving them after
      surgery may kill any remaining tumor cells. It is not yet known if adjuvant chemotherapy is
      more effective when given immediately after radical cystectomy (surgery to remove the
      bladder) or when the cancer returns.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the overall and progression-free survival of patients with stage III or IV
      transitional cell carcinoma of the bladder urothelium treated with immediate versus deferred
      adjuvant chemotherapy after radical cystectomy.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center, tumor status (pT1-2 vs pT3 vs pT4), and node status (node positive vs
      node negative with 15 or more nodes sampled vs node negative with less than 15 nodes
      sampled). Patients are randomized to one of two treatment arms.

      ARM I: Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses
      of adjuvant chemotherapy.

      ARM II: Beginning at the time of clinical relapse, patients receive a total of 6 courses of
      adjuvant chemotherapy.

      Patients in both arms receive one of the following chemotherapy regimens to be determined by
      participating center:

      REGIMEN A (Classical M-VAC): Patients receive classical M-VAC comprising methotrexate IV on
      days 1, 15 and 22; vinblastine IV on days 2, 15, and 22; and doxorubicin IV and cisplatin IV
      on day 2. Courses repeat every 28 days.

      REGIMEN B (High-dose M-VAC): Patients receive high-dose M-VAC comprising methotrexate IV on
      day 1 and vinblastine IV, doxorubicin IV, and cisplatin IV on day 2. Patients also receive
      filgrastim (G-CSF subcutaneously once daily on days 4-10. Courses repeat every 14 days.

      REGIMEN C (Gemcitabine and cisplatin): Patients receive gemcitabine IV over 30 minutes on
      days 1, 8, and 15 followed by cisplatin IV on day 1 or 2. Courses repeat every 28 days.

      Patients are followed every 3 months for 1 year, every 6 months for 5 years, and then
      annually thereafter.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK and EORTC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of survival</measure>
    <time_frame>5 years</time_frame>
    <description>Estimated using the Kaplan-Meier technique and compared based on a two sided logrank test with retrospective stratification for the participating cooperative group, the chemotherapy regimen, the T category and the nodal status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Estimated using the Kaplan-Meier technique and compared based on a two sided logrank test with retrospective stratification for the participating cooperative group, the chemotherapy regimen, the T category and the nodal status.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Stage III Bladder Cancer</condition>
  <condition>Stage IV Bladder Cancer</condition>
  <condition>Transitional Cell Carcinoma of the Bladder</condition>
  <arm_group>
    <arm_group_label>Arm I (immediate chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (deferred chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (immediate chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (deferred chemotherapy)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (immediate chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (deferred chemotherapy)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (immediate chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (deferred chemotherapy)</arm_group_label>
    <other_name>29060-LE</other_name>
    <other_name>Exal</other_name>
    <other_name>Velban</other_name>
    <other_name>Velbe</other_name>
    <other_name>Velsar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (immediate chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (deferred chemotherapy)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (immediate chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (deferred chemotherapy)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (immediate chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (deferred chemotherapy)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed transitional cell carcinoma of the bladder urothelium

               -  T3-4, N1-3, M0

          -  No pure squamous cell or adenocarcinoma tumors

          -  No more than 90 days since prior radical cystectomy and bilateral lymphadenectomy
             without evidence of microscopic residual disease

          -  Performance status - WHO 0-1

          -  WBC at least 3,500/mm^3

          -  Platelet count at least 120,000/mm^3

          -  SGOT/SGPT less than 2.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase less than 2.5 times ULN

          -  Bilirubin normal

          -  Glomerular filtration rate greater than 60 mL/min

          -  No clinically significant cardiac arrhythmia

          -  No congestive heart failure

          -  No complete bundle branch block

          -  No New York Heart Association class III or IV heart disease

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 6 months after study

          -  Considered fit for cisplatin-containing combination chemotherapy

          -  No clinically abnormal auditory function

          -  No known hypersensitivity to E. coli-derived drug preparations

          -  No grade 2 or greater peripheral neuropathy

          -  No other prior or concurrent malignancy except adequately treated carcinoma in situ of
             the cervix, treated basal cell skin cancer, or treated incidental prostate cancer
             (pT2, Gleason score no greater than 6, and PSA less than 0.5 ng/mL)

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study involvement

          -  No prior systemic chemotherapy

          -  No prior radiotherapy to the bladder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cora Sternberg, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>San Camillo Forlanini Hospitals</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.eortc.be/clinicaltrials/details.asp?protocol=30994</url>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

